ASLAN Pharmaceuticals (NASDAQ:ASLN) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of ASLAN Pharmaceuticals (NASDAQ:ASLN) in a research note issued to investors on Monday, Benzinga reports. They currently have a $9.00 price target on the stock.

Separately, Piper Sandler reiterated an overweight rating and set a $10.00 price objective (down from $15.00) on shares of ASLAN Pharmaceuticals in a research report on Wednesday, March 13th.

ASLAN Pharmaceuticals Stock Performance

Shares of NASDAQ ASLN opened at $0.49 on Monday. The stock has a 50 day simple moving average of $0.61 and a 200-day simple moving average of $0.76. The company has a market cap of $8.03 million, a PE ratio of -0.18 and a beta of 1.45. ASLAN Pharmaceuticals has a 12-month low of $0.39 and a 12-month high of $4.69.

Hedge Funds Weigh In On ASLAN Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in ASLN. UBS Group AG bought a new stake in ASLAN Pharmaceuticals during the fourth quarter worth approximately $326,000. Schonfeld Strategic Advisors LLC raised its holdings in ASLAN Pharmaceuticals by 68.2% during the third quarter. Schonfeld Strategic Advisors LLC now owns 91,500 shares of the company’s stock worth $172,000 after purchasing an additional 37,100 shares in the last quarter. Virtu Financial LLC raised its holdings in ASLAN Pharmaceuticals by 389.6% during the fourth quarter. Virtu Financial LLC now owns 88,106 shares of the company’s stock worth $32,000 after purchasing an additional 70,109 shares in the last quarter. Millennium Management LLC raised its holdings in ASLAN Pharmaceuticals by 4.1% during the fourth quarter. Millennium Management LLC now owns 1,654,153 shares of the company’s stock worth $595,000 after purchasing an additional 64,784 shares in the last quarter. Finally, Citigroup Inc. bought a new stake in ASLAN Pharmaceuticals during the fourth quarter worth approximately $104,000. 58.82% of the stock is currently owned by institutional investors and hedge funds.

ASLAN Pharmaceuticals Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.